Countries China
Innovent and ASK Pharm Secure NMPA Approval for Limertinib in EGFR T790M-Mutated NSCLC
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
January 20, 2025 | News
Zai Lab’s KarXT NDA Accepted by China’s NMPA for Schizophrenia Treatment
Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the ...
January 20, 2025 | News
Guangzhou Fermion Partners with Simcere to Advance Clinical-Stage SSTR4 Agonist for Pain Management
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment ass...
January 20, 2025 | News
Innovent and ASK Pharm Secure NMPA Approval for Limertinib to Treat EGFR T790M-Mutated NSCLC
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
January 17, 2025 | News
IMPACT Therapeutics’ Senaparib Gains NMPA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthet...
January 17, 2025 | News
Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
January 16, 2025 | News
CARsgen Therapeutics Administers First Dose of Allogeneic CAR T-Cell Therapy KJ-C2219 in Investigator-Initiated Trial
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...
January 14, 2025 | News
Simcere Zaiming and AbbVie Partner to Advance Novel Trispecific Antibody for Multiple Myeloma Treatment
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement ...
January 14, 2025 | News
China Approves Sarclisa-Pd for Relapsed Multiple Myeloma, Backed by Pivotal Trial and Real-World Data.
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa ...
January 13, 2025 | News
WuXi AppTec Joins Pharmaceutical Supply Chain Initiative, Strengthening Commitment to Responsible Business Practices
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life scie...
January 13, 2025 | News
Sciwind Biosciences Partners with Verdiva Bio in $2.4 Billion Deal to Advance Global Metabolic Disease Therapies
Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, ...
January 13, 2025 | News
JW Therapeutics' Carteyva® Secures Breakthrough Therapy Designation in China for Relapsed/Refractory Large B-Cell Lymphoma
W Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing ce...
January 13, 2025 | News
Kelun-Biotech and Harbour BioMed Ink $970 Million Licensing Deal with Windward Bio for Anti-TSLP Antibody
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (togeth...
January 13, 2025 | News
MSD’s GARDASIL® Becomes First HPV Vaccine Approved for Males in China
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the National Medical Products Administration (NMPA) of China ...
January 10, 2025 | News
Most Read
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
